All Resources

Alberta Health and Wellness product listing agreement policy

Description

This policy defines clear parameters to establish and execute PLA’s (Product Listing Agreement) through a collaborative, predictable and sustainable process between government and industry.

Tags

Alberta Pharmaceutical Strategy phase two : Alberta pharmaceutical strategy

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy... More ≫

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy included two phases. This fact sheet provides an overview of the second phase of the strategy, which was announced in October 2009. This phase focuses on generic drug prices and expanding the roles of pharmacists.

Tags

Alberta Pharmaceutical Strategy phase two : generic drugs

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy... More ≫

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy included two phases. The second phase, announced in October 2009, focuses on generic drug prices and expanding the roles of pharmacists. This fact sheet focuses on how generic drugs will be approached in this second phase of the strategy.

Tags

Alberta Pharmaceutical Strategy phase two : brand name drugs

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy... More ≫

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy included two phases. The second phase, announced in October 2009, focuses on generic drug prices and expanding the roles of pharmacists. This fact sheet focuses on how brand name drugs will be approached in this second phase of the strategy.

Tags

Alberta pharmaceutical strategy [2009]

Description

Alberta Health and Wellness announced the creation of a Health Action Plan for Alberta in April 2008. A key component of this plan is the development of a pharmaceutical strategy. The majority of... More ≫

Description

Alberta Health and Wellness announced the creation of a Health Action Plan for Alberta in April 2008. A key component of this plan is the development of a pharmaceutical strategy. The majority of working Albertans are not covered by government-sponsored programs, and spending on drugs is increasing at a rate three times higher than that of physician or hospital services. To support the development of an Alberta Pharmaceutical Strategy, two consultations were undertaken in 2008. The Strategy outlined in this document is a response to the findings and recommendations of these consultations, and its goal is to make drug coverage more accessible, affordable, efficient and therapeutically effective.

Tags

Alberta pharmaceutical strategy [2008]

Description

Alberta Health and Wellness announced the creation of a Health Action Plan for Alberta in April 2008. A key component of this plan is the development of a pharmaceutical strategy. The majority of... More ≫

Description

Alberta Health and Wellness announced the creation of a Health Action Plan for Alberta in April 2008. A key component of this plan is the development of a pharmaceutical strategy. The majority of working Albertans are not covered by government-sponsored programs, and spending on drugs is increasing at a rate three times higher than that of physician or hospital services. To support the development of an Alberta Pharmaceutical Strategy, two consultations were undertaken in 2008. The Strategy outlined in this document is a response to the findings and recommendations of these consultations, and its goal is to make drug coverage more accessible, affordable, efficient and therapeutically effective.

Tags

Alberta rare diseases drug program : fact sheet

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy... More ≫

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy was implemented in two phases. The first phase introduced a program to cover catastrophic drug costs for Albertans with rare diseases, which is briefly described in this fact sheet.

Tags

Drug approval process : fact sheet

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy... More ≫

Description

In December 2008, Alberta Health and Wellness announced the Alberta Pharmaceutical Strategy to help make drug coverage more accessible, sustainable and affordable for all Albertans. The strategy was implemented in two phases. The first phase included an improved drug approval process, which is briefly described in this fact sheet.

Tags

Alberta pharmaceutical strategy : stakeholder consultation

Description

A Health Action Plan for Alberta was announced by the Minister of Health and Wellness in April 2008. A key component of this plan is the development of a pharmaceutical strategy. A consultation... More ≫

Description

A Health Action Plan for Alberta was announced by the Minister of Health and Wellness in April 2008. A key component of this plan is the development of a pharmaceutical strategy. A consultation process was implemented to meet key stakeholders, summarize their comments, and make key recommendations. Meetings were held with 16 stakeholder groups representing patients, physicians, pharmacists, employers, benefit providers, and the pharmaceutical industry. Written submissions were also welcomed. This document summarizes the stakeholders input and presents 10 recommendations for the government to implement.

Tags